We thank Naharci and Tasci
1
for their thoughtful comments regarding our recent article published in the Journal of the American Medical Directors Assoication.
2
They provided us with an opportunity to further increase the clinical value of our
finding relating to the association between acetylcholinesterase inhibitors (AChEIs)
and risk of fracture in patients with Alzheimer's disease (AD).To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the American Medical Directors AssociationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Naharci MI, Tasci I. Comment on association between acetylcholinesterase inhibitors and osteoporotic fractures in Alzheimer’s patients. J Am Med Dir Assoc. 2020;21:706-707.
- Association between acetylcholinesterase inhibitors and osteoporotic fractures in older persons with Alzheimer's disease.J Am Med Dir Assoc. 2020 Jan 8; ([Epub ahead of print])
- Use of proton pump inhibitors and the risk of cholangitis: A nationwide cohort study.Aliment Pharmacol Ther. 2019; 50: 760-768
- Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma.J Bone Miner Metab. 2020; 38: 254-263
- The association between polypharmacy and hip fracture in osteoporotic women: A nested case–control study in South Korea.Clin Drug Investig. 2019; 39: 63-71
Article info
Identification
Copyright
© 2020 AMDA - The Society for Post-Acute and Long-Term Care Medicine.
